The study’s primaryendpointwasobjectiveresponserate, the percentageofpatients whoexperiencedcompleteorpartialcancershrinkage or disappearanceaftertreatment.
The study met its primary endpoint of durable responserate (DRR), defined as the rate of complete or partialresponse lasting continuously for at least six months.